Temodal
What Temodal is used for
Temodal hard capsules is indicated for the treatment of: adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and subsequently as monotherapy treatment; children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Temodal
- Active substance
- temozolomide
- Disease area
- Glioma
- Medicine group
- Antineoplastic agents
- ATC code
- L01AX03
- Marketing authorisation holder
- Merck Sharp & Dohme B.V.
- Authorised in the EU since
- 1999
Official information
In the USA
Same active substance: Temodar
In India
- Temozolomide: 107 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Temodal used for?
Temodal hard capsules is indicated for the treatment of: adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and subsequently as monotherapy treatment; children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.
What is the active substance in Temodal?
Temodal contains temozolomide.
Who makes Temodal?
The EU marketing authorisation holder is Merck Sharp & Dohme B.V..
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU